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Background: The trastuzumab biosimilar CT-P6 has demonstrated equivalent efficacy
and comparable safety to reference trastuzumab (RTZ) in clinical trials of human epidermal
growth factor receptor 2 (HER2)-positive early breast cancer (EBC). Here, we present the
first real-world comparison of CT-P6 versus RTZ with dual HER2-targeted therapy for the
neoadjuvant and palliative first-line treatment with HER2-positive EBC and metastatic
breast cancer (MBC) patients in two tertiary hospitals in Korea.
Methods: We retrospectively investigated medical records in the Severance Breast
Cancer Registry in Korea. We identified patients with HER2-positive EBC (n=254) who
had received neoadjuvant chemotherapy with RTZ or CT-P6, plus pertuzumab,
carboplatin and docetaxel (TCHP) and untreated stage IV MBC (n=103) who had
received palliative first-line treatment with RTZ or CT-P6, plus pertuzumab and
docetaxel (THP) between May 2014 and December 2019. The primary endpoints were
pathologic complete response (pCR) in the EBC and progression-free survival (PFS) in the
MBC cohort. Overall survival (OS), overall response rate (ORR), disease control rate (DCR),
and cardiac safety were secondary endpoints.
Results: A similar percentage of EBC patients achieved a pCR with CT-P6 versus RTZ
(74.4% [93/125]) vs 69.8% [90/129], p=0.411). For patients with MBC, median follow-up
duration was 23.0 and 41.0 months for CT-P6 and RTZ groups, respectively; median PFS
did not differ significantly between two groups (13.0 vs 18.0 months, 95% confidence
intervals (CIs) 0.0-26.6 vs 11.3-24.7, p=0.976). The ORR, DCR, and cardiac safety
profiles did not also show significant difference efficacy outcomes between two groups.
Conclusions: These real-world data suggest that biosimilar trastuzumab CT-P6 has
similar effectiveness and cardiac safety to RTZ in HER2-positive EBC and MBC patients,June 2021 | Volume 11 | Article 6895871
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Frontiers in Oncology | www.frontiersin.orgwhen administered as part of dual HER2-targeted therapy with pertuzumab plus
chemotherapy in the neoadjuvant or palliative setting.Keywords: biosimilar, HER2-positive breast cancer, trastuzumab, CT-P6, early breast cancer (EBC), metastatic
breast cancer (mbc)INTRODUCTION
Breast cancer is a heterogeneous disease that has multiple
subtypes. Approximately 25% of breast cancers amplify the
human epidermal growth factor receptor 2 (HER2) oncogene,
resulting in a more aggressive phenotype with poorer prognosis
(1). The development of trastuzumab, a humanized monoclonal
antibody that binds to the HER2 extracellular domain, has
transformed the treatment of HER2-positive breast cancers (2)
and improved clinical responses (2–4) and disease free survival
(5). Trastuzumab is also effective in metastatic HER2-positive
breast cancer, with the addition of trastuzumab to standard
chemotherapy shown to extend the overall survival (OS) (6, 7).
However, the development of novel biologic agents is
expensive, which can translate into high drug costs (8). Despite
their efficacy, the costs associated with these drugs can pose a
burden on healthcare systems and create barriers to access. This
difficulty can be mitigated in part through the use of biosimilars
(8). A biosimilar is a drug that is highly similar to an existing
drug, the originator or reference product, and which shows no
clinically meaningful differences in purity, safety, and efficacy (8).
Biosimilars are in general more affordable than their reference
products, and their availability has the potential to improve
patient access to safe and effective treatments.
Several biosimilars of trastuzumab have been developed,
including CT-P6 (Herzuma®; Celltrion Inc., Incheon, Republic
of Korea) (9, 10), SB3 (Ontruzant®; Samsung Bioepis Co., Ltd),
(11) ABP 980 (Kanjinti®; Amgen) (12) and PF-05280014
(Trazimera®; Pfizer) (13). CT-P6 binds with high affinity and
specificity to the same HER2 epitope as the reference product,
Herceptin® (Genentech) (9, 10). In 2018, CT-P6 was approved
by the US Food and Drug Administration and the European
Medicines Agency for the treatment of HER2-positive early
(EBC) and metastatic breast cancer (MBC) (14–17).
Real-world studies are an important supplement to clinical
trials, by revealing the long-term safety and effectiveness of drugs
in broader patient populations, as well as in other settings and in
combination with other treatments. For example, reference
trastuzumab (RTZ) is now increasingly used in combination
with pertuzumab (Perjeta®; Genentech) as part of dual HER2-
targeted therapy. Pertuzumab is a monoclonal antibody that
targets a different region of the HER2 receptor to trastuzumab,
(18) and thus has a complementary mode of action. Dual HER2-
targeting with trastuzumab and pertuzumab, plus chemotherapy,
has been shown to improve clinical responses compared to
trastuzumab alone plus chemotherapy in HER2-positive EBC
(19, 20) and MBC (21).
Here we present the results of the first real-world comparison
of the effectiveness of CT-P6 and RTZ when administered with
pertuzumab plus chemotherapy in the neoadjuvant treatment to2
patients with HER2-positive EBC or in the palliative first-line
treatment to patients with MBC. As cardiotoxicity is a potentially
serious adverse effect associated with the use of trastuzumab, (6)
we also assessed the cardiac safety of CT-P6 and the RTZ.MATERIALS AND METHODS
Patients
We retrospectively investigated medical records in the Severance
Breast Cancer Registry at the Yonsei Cancer Center and
Gangnam Severance Hospital in Seoul, Republic of Korea
(Figure 1). We identified patients with HER2-positive EBC
who had undergone neoadjuvant chemotherapy between April
2015 and October 2019, as well as patients with newly diagnosed
de novo or recurrent HER2-positive MBC who had undergone
palliative chemotherapy between May 2014 and December 2019.
For both the EBC and MBC cohorts, eligible patients were
women aged >19 years with a histologically confirmed
diagnosis of HER2-positive breast cancer.
EBC was defined as clinical stage II–III, classified according to
the American Joint Committee on Cancer Breast Cancer Staging
seventh edition. In MBC cohort, eligible patients had no previous
palliative treatment in advanced disease and received
chemotherapy with or without trastuzumab in the neoadjuvant
or adjuvant setting, provided there was a minimum 12-month
interval between completion of all therapy and the diagnosis of
metastatic disease.
Procedures
In the EBC cohort, neoadjuvant docetaxel (T)-carboplatin (C)-
RTZ or CT-P6 (H)-pertuzumab (P) (TCHP) treatment was
administered via intravenous infusion every 3 weeks, for a
total of six cycles, in accordance with procedures in the
TRYPHAENA trial (22). CT-P6 or RTZ were administered at a
loading dose of 8 mg/kg on cycle 1, and at a maintenance dose of
6 mg/kg on cycles 2–6. Pertuzumab was administered at a
loading dose of 840 mg, then a maintenance dose of 420 mg in
subsequent cycles. Carboplatin was administered at area under
the curve 5 or 6 and docetaxel at 75 mg/m2, in all cycles.
In the MBC cohort, palliative first-line docetaxel (T)-RTZ or
CT-P6 (H)-pertuzumab (P) (THP) regimen was administered
via intravenous infusion every 3 weeks, in accordance with
procedures in the CLEOPATRA trial (23). Pertuzumab,
docetaxel and RTZ or CT-P6 were given same doses and
schedules in neoadjuvant setting. Pertuzumab and RTZ or CT-
P6 were given until disease progression or unmanageable toxic
effects, and docetaxel was given for at least six cycles. If
chemotherapy was discontinued due to toxic effects,June 2021 | Volume 11 | Article 689587
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progression, or occurrence of unacceptable adverse events.Outcome Measures
The primary endpoints were pathologic complete response
(pCR) in the EBC and progression-free survival (PFS) in the
MBC cohort. pCR was assessed locally at the time of surgery and
was defined as the absence of invasive tumor cells during a
microscopic assessment of the primary tumor (ypT0/is) and
axilla (ypN0). Median PFS was defined as time from the date of
first-line palliative systemic treatment to the first documented
disease progression or death from any cause.
The secondary endpoints in the MBC cohort were median
overall survival (mOS), overall response rate (ORR) and disease
control rate (DCR). mOS was the time from the date of first-line
palliative systemic treatment to death from any cause. ORR was
defined as the proportion of patients who achieved a complete
response (CR) or confirmed partial response (cPR) per RECIST
1.1. DCR was defined as the proportion of patients who achieved
a CR, cPR, or stable disease (SD) per RECIST 1.1.
Cardiac safety was a secondary endpoint in both the EBC and
MBC cohorts. Left ventricular ejection fraction (LVEF) was
measured either by echocardiography or a multiple-gated
acquisition (MUGA) scan every 3 months. An adverse event
related to cardiac safety was defined as a decline in investigator-
assessed LVEF of ≥10 percentage points from baseline at any
time, or an LVEF of <50% at any time.Statistical Analysis
pCR rate was compared between treatment groups using the chi-
square test or Fisher’s exact test. To reduce baseline confoundersFrontiers in Oncology | www.frontiersin.org 3between the CT-P6 group and RTZ group, one-to-one
propensity score matching (PSM) was performed using the
nearest-neighbor matching method. Variables entered into the
PSM included age, histologic type, histologic grade, estrogen
receptor, progesterone receptor, subgroup, Ki67, clinical tumor
stage, and clinical node stage. PFS and OS were evaluated using
unadjusted log-rank tests and Cox proportional-hazards models.
Differences in ORR or DCR between the treatment groups were
evaluated using an adjusted Fisher’s exact test. The 95%
confidence intervals (CIs) for the ORRs were calculated
using an asymptotic normal approximation. A two-tailed
P-value <0.05 was considered statistically significant. The
statistical analysis was performed using IBM SPSS Statistics for
Windows, Version 23 software (IBM Corp. Armonk, NY, USA).RESULTS
Study Population of EBC and MBC
Cohorts
A total of 258 women with HER2-positive EBC were identified
who underwent neoadjuvant TCHP, followed by surgery
(Figure 1). Four patients were excluded owing to the presence
of bilateral breast lesions (n=3) or a history of DCIS/invasive
breast cancer (n=1). The remaining 254 women were analyzed in
this study. Baseline characteristics were similar between patients
who received CT-P6 (n=125, 49.2%) and those receiving RTZ
(n=129, 50.8%) (Table 1). A greater proportion of patients in the
CT-P6 had a Ki67 index ≥14 (CT-P6: 87.5% [84/125]; RTZ:
70.5% [55/129]; P=0.005). After adjusting for propensity scores,
all variables were well balanced between the CT-P6 and RTZ
groups (Supplementary Table 1).FIGURE 1 | Study profile. DCIS, ductal carcinoma in situ; EBC, early-stage breast cancer; HER2, human epidermal growth factor receptor 2; MBC, metastatic
breast cancer; RTZ, reference trastuzumab; TCHP, docetaxel–carboplatin–RTZ or CT-P6–pertuzumab.June 2021 | Volume 11 | Article 689587
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HER2-positive MBC were identified who received palliative first-
line treatment with THP between May 2014 and December 2019.
Eighteen patients were excluded because they received either
palliative RTZ monotherapy or palliative RTZ plus docetaxel. A
further 17 patients were excluded because they were switched
from RTZ to CT-P6. The remaining 103 women were analyzed
in this study. Baseline characteristics were similar for patients
who received CT-P6 (n=38, 36.9%) and RTZ (n=65, 63.1%)
(Table 1). The percentage of patients with de novo stage IV MBC
was 63.2% (24/38) in the CT-P6 and 72.3% (47/65) among those
who received RTZ. The most common sites of metastasis were
distant lymph nodes, followed by bone, lung, and liver.Frontiers in Oncology | www.frontiersin.org 4Effectiveness of EBC and MBC Cohorts
The percentage of EBC patients who achieved a pCR did not
differ between two groups (Figure 2A). Overall, 74.4% (93/125)
achieved a pCR with CT-P6 versus 69.8% (90/129) with RTZ
(P=0.411). Among patients with HR-positive EBC, 57.8% (26/45)
of patients who received CT-P6 achieved a pCR, compared with
44.4% (20/45) of patients who received RTZ (P=0.206). Among
patients with HR-negative, 83.8% (67/80) of patients who
received CT-P6 achieved a pCR, as did 83.3% (70/84) of
patients who received RTZ (P=0.943). Similarly, there was no
difference in pCR between the two groups in the PSM cohort,
regardless of subtype (Figure 2B).TABLE 1 | Baseline characteristics of patients with HER2-positive early-stage and metastatic breast cancer.
Early-stage breast cancer Metastatic breast cancer
RTZ (n=129) CT-P6 (n=125) Total (N=254) P-value RTZ (n=65) CT-P6 (n=38) Total (N=103) P-value
Age, median (range) 49 (22–75) 50 (27–71) 49 (22–75) 0.447 54 (31–76) 55 (28–79) 54 (28–79) 0.695
Stage IV, n (%) 0.333
De novo – – – 47 (72.3) 24 (63.2) 71 (68.9)
Recurrent – – – 18 (27.7) 14 (36.8) 32 (31.1)
Histology, n (%) <0.001 0.117
IDC 113 (87.6) 124 (99.2) 237 (93.3) 60 (93.8) 32 (86.5) 92 (91.1)
ILC 11 (8.5) 1 (0.8) 12 (4.7) 1 (1.6) 0 (0) 1 (1.0)
Othera 5 (3.9) 0 5 (2.0) 3 (4.7) 5 (13.5) 8 (7.9)
ER, n (%) 0.752 0.804
Positive 44 (34.1) 45 (36.0) 89 (35.0) 29 (44.6) 16 (42.1) 45 (43.7)
Negative 85 (65.9) 80 (64.0) 165 (65.0) 36 (55.4) 22 (57.9) 58 (56.3)
PR, n (%) 0.992 0.812
Positive 30 (23.3) 29 (23.2) 59 (23.2) 15 (23.1) 8 (21.1) 23 (22.3)
Negative 99 (76.7) 96 (76.8) 195 (76.8) 50 (76.9) 30 (78.9) 80 (77.7)
Subgroup, n (%) 0.852 0.804
HR+/HER2+ 45 (34.9) 45 (36.0) 90 (35.4) 29 (44.6) 16 (42.1) 45 (43.7)
HR−/HER2+ 84 (65.1) 80 (64.0) 164 (64.6) 36 (55.4) 22 (57.9) 58 (56.3)
HG,b n (%) 0.960 0.135
1 or 2 68 (73.1) 83 (72.8) 151 (72.9) 4 (36.4) 7 (70.0) 11 (52.4)
3 25 (26.9) 31 (27.2) 56 (27.1) 7 (63.6) 3 (30.0) 10 (47.6)
Ki67,b n (%) 0.005 0.647
<14 23 (29.5) 12 (12.5) 35 (20.1) 3 (11.1) 3 (11.5) 6 (11.3)
≥14 55 (70.5) 84 (87.5) 139 (79.9) 24 (88.9) 23 (88.5) 47 (88.7)
cT,c n (%) 0.139
1 or 2 85 (65.9) 93 (74.4) 178 (70.1) – – –
≥3 44 (34.1) 32 (25.6) 76 (29.9) – – –
cN,d n (%) 0.072
Negative 16 (12.4) 26 (20.8) 42 (16.5) – – –
Positive 113 (87.6) 99 (79.2) 212 (83.5) – – –
Metastasis site, n (%)
Distant LN – – – 39 (60.0) 19 (50.0) 58 (56.3) 0.323
Bone – – – 33 (50.8) 16 (42.1) 48 (47.6) 0.396
Lung – – – 21 (32.3) 14 (36.8) 35 (34.0) 0.639
Liver – – – 18 (29.2) 14 (36.8) 33 (32.0) 0.424
Breast skin – – – 4 (6.2) 6 (15.8) 10 (9.7) 0.107
Brain – – – 4 (6.2) 3 (7.9) 7 (6.8) 0.513
Pleural – – – 3 (4.6) 4 (10.5) 7 (6.8) 0.225
Othere – – – 9 (13.8) 2 (5.3) 11 (10.7) 0.151June 2021 | Volume 11 | ArticleaOther histology included micropapillary, apocrine, mucinous, and metaplastic carcinoma.
bValues were missing for some patients across groups.
ccT was based on tumor size measured by pre-treatment breast magnetic resonance imaging.
dcN positive was defined as axillary lymph node metastasis proven by fine-needle aspiration biopsy (FNAB), or suspicious axillary lymph node metastasis in the imaging study among
patients who did not receive FNAB.
eOther metastasis sites included adrenal gland, peritoneum, and soft tissue mass.
cN, clinical node stage; cT, clinical tumor stage; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HG, histologic grade; HR, hormone receptor; IDC, invasive
ductal carcinoma; ILC, invasive lobular carcinoma; LN, lymph node; PR, progesterone receptor; RTZ, reference trastuzumab.689587
Bae et al. Real-World Data for CT-P6The median follow-up time (range) was 23.0 (3.0-36.0) and 41.0
(1.0-83.0) months for MBC patients who received CT-P6 and RTZ.
MBC patients in the CT-P6 received a median (range) of 23.0 (3–
54) cycles while those in the RTZ received a median (range) of 26.0
(1-99) cycles. Median PFS did not differ significantly between two
groups (CT-P6 vs RTZ: 13.0 vs 18.0 months [95% CI 0.0-26.6 vs
11.3-24.7]; P=0.976) (Figure 3A). There was also no statistically
significant difference in median PFS between the two treatment
groups regardless of HR status (HR-positive: CT-P6 vs RTZ 10.0 vs
17.0 months [95% CI 0.0-23.7 vs 10.0-24.0], P=0.721; HR-negative:
13.0 vs 21.0 months [95% CI NA vs 12.9-29.1], P=0.875)
(Figures 3B, C). There was also no significant difference in mOS
between CT-P6 and RTZ groups (not reached vs not reached,
P=0.330) and regardless of HR status (data not shown). The ORR
and DCR did not differ significantly (ORR: CT-P6 vs RTZ 78.9% vs
83.1%, P=0.602; DCR: 94.7% vs 93.8%, P>0.999) and also according
to HR status (Table 2).
Cardiac Safety of EBC and MBC Cohorts
In EBC cohort, the rate of LVEF did not differ between the two
treatment groups before (mean [95% CI] LVEF: CT-P6: 68.1%Frontiers in Oncology | www.frontiersin.org 5[67.0–69.1] versus RTZ: 68.1% [67.1–69.1]; P=0.983) or after
neoadjuvant chemotherapy (CT-P6: 65.9% [65.0–66.8] versus
RTZ: 66.5% [65.3–67.7]; P=0.424) (Supplementary Figure 1).
After neoadjuvant chemotherapy, 23/104 (22.1%) patients
showed a decrease in LVEF of ≥10 percentage points from
baseline in the CT-P6, compared with 13/90 (14.4%) patients
in the RTZ (P=0.171). No patients in either treatment group
showed a decrease in LVEF to <50% at any point.
In MBC cohort, both CT-P6 and RTZ showed a manageable
cardiac safety profile, assessed with LVEF (Supplementary
Figure 2). Nineteen out of 38 (50.0%) patients in the CT-P6
experienced a decline in LVEF of ≥10 percentage points from
baseline, compared with 27/63 (42.9%) patients in the RTZ
(P=0.695). Among those who received treatment with CT-P6,
3/38 (7.9%) patients experienced a reduction in LVEF to <50% at
any time. One of these patients discontinued CT-P6 for 1 month
before re-starting; the others continued treatment but later
discontinued after 3 months owing to progressive disease.
Among the patients who received treatment with RTZ, 4/65
(6.2%) experienced a reduction in LVEF to <50% at any time.
Two of these patients discontinued treatment with RTZ, oneA
B
FIGURE 2 | Percentage of patients with HER2-positive early-stage breast cancer who achieved a pCR following CT-P6 or RTZ treatment, stratified by HR status for
(A) all patients and (B) propensity score matching cohort. HER2, human epidermal growth factor receptor 2; HR, hormone receptor; pCR, pathologic complete
response; RTZ, reference trastuzumab.June 2021 | Volume 11 | Article 689587
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continued treatment with RTZ.DISCUSSION
To our knowledge, this is the first real-world study to show that
CT-P6 has similar effectiveness and cardiac safety to RTZ in
patients with HER2-positive EBC and MBC, when administeredFrontiers in Oncology | www.frontiersin.org 6as part of dual HER2-targeted therapy with pertuzumab and
chemotherapy in the neoadjuvant or palliative setting.
This study reported the similar pCR in the neoadjuvant
setting for HER2-positive breast cancer with RTZ and CT-P6.
Almost 75% of patients with HER2-positive EBC who received
CT-P6 achieved a pCR, compared with around 70% of patients
who received RTZ. In the EBC cohort, a significantly greater
percentage of patients in the CT-P6 versus RTZ treatment group
had a Ki67 index ≥14 at baseline (87.5% versus 70.5%; P=0.005).A
B
C
FIGURE 3 | PFS for HER2-positive metastatic breast cancer patients who received palliative treatment with CT-P6 or RTZ for (A) all patients, (B) HR+/HER2+
patients, and (C) HR−/HER2+ patients. HER2, human epidermal growth factor receptor 2; HR, hormone receptor; PFS, progression-free survival; RTZ, reference
trastuzumab.June 2021 | Volume 11 | Article 689587
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pCR in patients with breast cancer who receive neoadjuvant
chemotherapy (24, 25). Therefore, we implemented PSM to
reduce confounding bias: in the PSM cohort, there was no
difference in response to treatment between the two groups,
similar to the findings for the whole EBC cohort.
In the phase III randomized controlled trial that established the
equivalence of CT-P6 and the reference product, no pertuzumab
was added to the neoadjuvant regimen (16). However, since the dual
HER2-targeted approach may further improve pCR rates compared
with use of either RTZ alone (19, 23, 26, 27), most patients with
HER2-positive breast cancer who received neoadjuvant
chemotherapy at our institutions were treated with TCHP from
2018, when CT-P6 was approved. For this reason, we compared the
efficacy of CT-P6 and RTZ among patients with HER2-positive
EBC who received neoadjuvant TCHP. This study confirmed for
the first time in routine clinical practice that CT-P6 is at least as
effective as RTZ when administered as part of dual HER2-targeted
therapy with pertuzumab.
This study also provided the first real-world evidence that
CT-P6 is as effective as RTZ in patients with HER2-positive
MBC, when administered with pertuzumab and docetaxel. In the
CLEOPATRA trial, first-line treatment with improved PFS in
patients with HER2-positive MBC compared with placebo-
trastuzumab-docetaxel (18.5 vs 12.4 months; P<0.001) (23),
and extended OS (56.5 vs 40.8 months; P<0.001) (21). A real-
world study of patients with HER2-positive MBC in Italy
observed a response rate of 77.3% with pertuzumab-
trastuzumab-taxane, along with a median PFS of 21 months
(28). These results are consistent with those of this study, in
which the ORR was 78.9% with CT-P6-pertuzumab-docetaxel
and 83.1% with RTZ-pertuzumab-docetaxel. There was also no
significant difference in median PFS between patients who
received CT-P6 or RTZ in this study (13.0 vs 18.0 months;
P=0.976). While not statistically significant, the numerical
difference in PFS between the treatment groups may reflect the
shorter follow-up time for the CT-P6 group than RTZ (23.0 vs
41.0 months, respectively). However, since a relatively large
number of censored events occurred early in the follow-up
period for CT-P6, but later in the follow-up period for RTZ, aFrontiers in Oncology | www.frontiersin.org 7longer-term follow-up analysis will be required to confirm the
equivalence of CT-P6 and RTZ with respect to median PFS.
Use of trastuzumab has historically been associated with an
increased risk of cardiotoxicity (6), most often in the form of an
asymptomatic decline in LVEF. In this study, neither CT-P6 nor
RTZ showed serious cardiac toxicity profiles. No patients with EBC
experienced a reduction in LVEF of <50% in either treatment group,
consistent with the low cardiotoxicity observed in patients with EBC
treated with RTZ or CT-P6 in the neoadjuvant (16, 20) and
adjuvant (17, 20) settings. In this study, 7.9% (3/38) patients with
MBC experienced a decline in LVEF to <50% with CT-P6, as did
6.2% (4/65) patients with RTZ. A similar decline in LVEF was
observed in 6.1% of patients treated with pertuzumab-trastuzumab-
docetaxel in the CLEOPATRA trial (21).
One strength of our study is that it included a broader patient
population, that is more representative of the patient population as a
whole than the highly selected individuals recruited into clinical
trials. This is also the first study to compare the efficacy and safety of
CT-P6 and RTZ in both EBC and MBC based on data from two
institutions in Korea. There were also limitations: firstly, the study
had a retrospective design and a relatively small sample size.
Therefore, further prospective and larger studies are warranted.
Secondly, the follow-up time for patients who received CT-P6 was
shorter than for those who received RTZ. While the analysis found
no significant difference in median PFS with CT-P6 versus RTZ, a
longer follow-up period will be required to confirm their
equivalence with respect to PFS, as well as OS.
Biosimilar drugs are a biological product that is highly similar to
a licensed original product with clinical relevance in terms of safety,
potency, and efficacy. The development of biosimilar drugs is
necessary for reducing health costs and increasing global access to
cancer treatment. Therefore, regulatory agencies [European
Medicines Agency (EMA) and Food and Drug Administration
(FDA)] have tried to approve drug development, change clinical
practice and enter the market (29). Despite the established safety
and efficacy profile of RTZ in HER2 positive breast cancer, the
high cost of the drug remains a barrier to access, particularly in
healthcare systems with fewer resources. For example, a study
in China found that patients with HER2-positive EBC who lived
in areas with a relatively high gross domestic product were moreTABLE 2 | Best overall response, based on RECIST 1.1 criteria, according to palliative treatment in patients with HER2-positive metastatic breast cancer.
All patients HR+/HER2+ HR−/HER2+
RTZ (n=65) CT-P6 (n=38) P-value RTZ (n=29) CT-P6 (n=16) P-value RTZ (n=36) CT-P6 (n=22) P-value
Overall response 0.706a 0.902a 0.389a
CR, n (%) 5 (7.7) 2 (5.3) 3 (10.3) 1 (6.3) 2 (5.6) 1 (4.5)
PR, n (%) 49 (75.4) 28 (73.7) 18 (62.1) 11 (68.8) 31 (86.1) 17 (77.3)
SD, n (%) 7 (10.8) 6 (15.8) 5 (17.2) 4 (25.0) 2 (5.6) 2 (9.1)
PD, n (%) 2 (3.1) 2 (5.3) 2 (6.9) 0 0 2 (9.1)
NA, n (%) 2 (3.1) 0 1 (3.4) 0 1 (2.8) 0
Overall response rate 0.602 >0.999a 0.409a
CR/PR, n (%) 54 (83.1) 30 (78.9) 21 (72.4) 12 (75.0) 33 (91.7) 18 (81.8)
Disease control rate >0.999a 0.542a 0.551a
CR/PR/SD, n (%) 61 (93.8) 36 (94.7) 26 (89.7) 16 (100.0) 35 (97.2) 20 (90.9)June 2021 | Volume 11 | ArticleaFisher’s exact test.
CR, complete response; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NA, not available; PD, progressive disease; PR, partial response; RECIST 1.1,
Response Evaluation Criteria in Solid Tumors version 1.1; RTZ, reference trastuzumab; SD, stable disease.689587
Bae et al. Real-World Data for CT-P6likely to receive RTZ than those in areas with a lower gross domestic
product (30). The same study reported better survival outcomes in
patients with EBC or MBC who received treatment with RTZ,
illustrating how the high cost of RTZ can deprive patients of
effective treatments. As in previous studies (8, 31, 32), the results
of this study also suggest that biosimilar trastuzumab may provide
treatment as safe and effective as RTZ, but at a remarkably presented
opportunity for cost-saving and thereby to improved access for
patients of HER2 positive breast cancer.This real-world study
suggests that the biosimilar CT-P6 has similar effectiveness and
cardiac safety to RTZ in HER2-positive EBC and MBC, when
administered as part of dual HER2-targetd therapy with
pertuzumab and chemotherapy in the neoadjuvant or palliative
first-line setting. CT-P6 was well tolerated, with a cardiac safety
profile similar to that of the RTZ. The increased use of biosimilars
such as CT-P6 has the potential to boost access to life-extending
treatments for women with HER2-positive breast cancer.DATA AVAILABILITY STATEMENT
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